Skip to content
P

Pallavi Patri

Publications (3)

Chimeric Antigen Receptor-T Cell (CAR-T Cell) Therapy in Advanced Renal Cell Carcinoma

Brian Mark Churchill, Pallavi Patri, Jula K. Inrig, Anju Gopan, Ekaterina Vorozheikina, Luis Mendoza, Lara Kristina Donato & Ruma Pal Ghosh · International Research Journal of Oncology · 2021

With introduction of immunotherapy, the treatment of advanced renal cell carcinoma has undergone a substantial change. Immunotherapeutic agents including nivolumab, ipilimumab, pembrolizumab, have been introduced and approved for therapy of this life-threatening malignancy. Chime...

Open access Research Article

TNF-α, TNF Receptors and Their Complex Implications in Therapy

Brian Mark Churchill, Pallavi Patri, Rashna Cama & Jula K. Inrig · Asian Journal of Immunology · 2020

Tumor necrosis factor alpha (TNF-α), also called cachectin or cachexin, is a naturally occurring cytokine produced by activated macrophages and monocytes, and to a smaller scale by T-lymphocytes, B-lymphocytes, fibroblasts and astrocytes. It has both inflammatory and immunomodula...

Open access Research Article

IgA Vasculitis in a Patient on Dialysis

Deepak Kumar Chitralli, Brian Mark Churchill, Pallavi Patri & Divya Puttegowda · Asian Journal of Research in Nephrology · 2020

Immunoglobulin A vasculitis (IgA Vasculitis), formerly called Henoch Schonlein Purpura (HSP) is a common systemic vasculitis in children. It is 33 times less common in adults than in children. Besides having dermatology manifestations in form of rash, it may affect other organs i...

Open access Research Article